LynnGFeunMD

Professor, Medicine, University of Miami School of Medicine

Dr. Feun is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1475 NW 12th Ave
Miami, FL 33136
Phone+1 305-243-6606

Fax+1 305-243-5239

Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 1977 - 1979
Wayne State University School of MedicineResidency, Internal Medicine, 1976 - 1977
Wayne State University School of MedicineClass of 1974

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Super Doctor SuperDoctors.com

PubMed

122 citations
Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma
Lynn G. Feun, Ying-Ying Li, Chunjing Wu, Medhi Wangpaichitr, Patricia D. Jones
Cancer. 2019-10-15
36 citations
Liver Transplantation for Hepatocellular Carcinoma in the Model for End-Stage Liver Disease Era
David Levi, Andreas G. Tzakis, Paul J. Martin, Seigo Nishida, Eddie Island
Journal of the American College of Surgeons. 2010-05-01
36 citations
Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group study.
Robert P. Whitehead, Kenneth J. Kopecky, Michael K. Samson, Costanzi Jj, Natale Rb
Journal of the National Cancer Institute. 1991-09-04

Lectures

Plasma biomarkers to predict pembrolizumab response in HCC patients.
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
Phase II study of pembrolizumab in advanced, unresectable hepatocellular carcinoma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Arginine Deprivation: A Targeted Therapy For MelanomaNational Cancer Institute2004–2006
New Therapeutic Approaches For Malignant GliomaNational Cancer Institute1993–1995